[
  {
    "ts": null,
    "headline": "U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system",
    "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity blood pressure procedure. This final determination will now provide Medicare patients with access to the Symplicity blood pressure procedure for the treatment of uncontrolled hyp",
    "url": "https://finnhub.io/api/news?id=205ab0d6ca5f6af9ce5dbd0323b1fbff0aa7d4f35d75254b86ea3e2599f393fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761690960,
      "headline": "U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system",
      "id": 137243746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity blood pressure procedure. This final determination will now provide Medicare patients with access to the Symplicity blood pressure procedure for the treatment of uncontrolled hyp",
      "url": "https://finnhub.io/api/news?id=205ab0d6ca5f6af9ce5dbd0323b1fbff0aa7d4f35d75254b86ea3e2599f393fb"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
    "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
    "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660375,
      "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
      "id": 137240047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940034961/image_1940034961.jpg?io=getty-c-w1536",
      "related": "MDT",
      "source": "SeekingAlpha",
      "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
      "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807"
    }
  },
  {
    "ts": null,
    "headline": "United States Insulin Pump Market Outlook and Company Analysis Report 2025-2033 Featuring Medtronic, Insulet, Tandem Diabetes Care, Roche, Ypsomed, Microtech Medical",
    "summary": "The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a CAGR of 5.84% from 2025-2033. This growth is driven by the rising diabetes prevalence, technological innovations in insulin delivery, and increased awareness of continuous glucose monitoring and personalized diabetes care. Key players like Medtronic, Insulet, and Tandem Diabetes Care are leading the market with smart insulin pumps integrated with CGMs for automated and rem",
    "url": "https://finnhub.io/api/news?id=a9798b38d01aa9594aca79216ba0c1d4b875f2dbe966d66c27bc2e6a70badb59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761653580,
      "headline": "United States Insulin Pump Market Outlook and Company Analysis Report 2025-2033 Featuring Medtronic, Insulet, Tandem Diabetes Care, Roche, Ypsomed, Microtech Medical",
      "id": 137238003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a CAGR of 5.84% from 2025-2033. This growth is driven by the rising diabetes prevalence, technological innovations in insulin delivery, and increased awareness of continuous glucose monitoring and personalized diabetes care. Key players like Medtronic, Insulet, and Tandem Diabetes Care are leading the market with smart insulin pumps integrated with CGMs for automated and rem",
      "url": "https://finnhub.io/api/news?id=a9798b38d01aa9594aca79216ba0c1d4b875f2dbe966d66c27bc2e6a70badb59"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic links renal denervation to 3-year blood pressure reduction",
    "summary": "Patients treated with Symplicity Spyral had significantly lower blood pressure than people who received a sham treatment after three years.",
    "url": "https://finnhub.io/api/news?id=1c0c42e3f260fb9d83b5c2f61cab8d8f813e3b347b4588f1422982187911449c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648540,
      "headline": "Medtronic links renal denervation to 3-year blood pressure reduction",
      "id": 137243747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Patients treated with Symplicity Spyral had significantly lower blood pressure than people who received a sham treatment after three years.",
      "url": "https://finnhub.io/api/news?id=1c0c42e3f260fb9d83b5c2f61cab8d8f813e3b347b4588f1422982187911449c"
    }
  }
]